Cargando…
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
Autores principales: | van der Horst, Hilma J., Oostindie, Simone C., Cillessen, Saskia. A. G. M., Gelderloos, Anne T., Overdijk, Marije B., Nijhof, Inger. S., Zweegman, Sonja, Chamuleau, Martine E. D., Breij, Esther C. W., Mutis, Tuna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732266/ https://www.ncbi.nlm.nih.gov/pubmed/33324950 http://dx.doi.org/10.1097/HS9.0000000000000504 |
Ejemplares similares
-
DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
por: Oostindie, Simone C., et al.
Publicado: (2020) -
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020) -
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019) -
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
por: van der Horst, Hilma J., et al.
Publicado: (2021) -
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)